fda warning letters compounding semaglutide october 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of September 8, 2025: FDA launches
Description
Patients on pemvidutide experienced only 21.9% of weight loss attributable to lean mass
Our deep and diverse obesity clinical pipeline is built to attempt to address critical gaps in care and meet patients where they are with optionality
What gives?
Could GLP-1 analogs or SGLT-2 inhibitors be beneficial for glycemic and weight control in patients on antidepressant medications?
These statements have not been evaluated by the Food and Drug Administration
